Furthermore, the shorter survival of p53 wild-type OCS compared to p53 mutant OCS argues against misclassification because patients with ovarian endometrioid carcinomas have a longer survival compared to HGSC (3). The gene discussed is TP53; the disease is ovarian endometrioid carcinoma.